 | |
| Clinical data | |
|---|---|
| Trade names | Ameile |
| Other names | Almonertinib; HS-10296 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C30H35N7O2 |
| Molar mass | 525.657 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Aumolertinib (trade nameAmeile) is a pharmaceutical drug for the treatment of cancer.[1] It is anepidermal growth factor receptor (EGFR)tyrosine kinase inhibitor (TKI).[2]
In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positivenon-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy.[3][4]
In December 2025, theCommittee for Medicinal Products for Human Use of theEuropean Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Aumseqa, intended for the treatment of non-small cell lung cancer (NSCLC).[5] The applicant for this medicinal product is SFL Pharmaceuticals Deutschland GmbH.[5]
